Advanced Enzyme Technologies Ltd
NSE:ADVENZYMES
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Advanced Enzyme Technologies Ltd
NSE:ADVENZYMES
|
IN |
Advanced Enzyme Technologies Ltd
Advanced Enzyme Technologies Ltd. engages in the research, development, manufacture, and sale of enzyme products. The company is headquartered in Thane, Maharashtra and currently employs 322 full-time employees. The company went IPO on 2016-08-01. The firm is focused on the research and development, manufacturing and marketing of approximately 400 products, which is developed from over 68 indigenous enzymes and probiotics. The company provides solutions to various industries, such as human health care and nutrition, animal nutrition, baking, fruit and vegetable processing, brewing and malting, grain processing, protein modification, dairy processing, specialty applications, textile processing and others. The company offers products and solutions for human nutrition, which include serratiopeptidase, fungal lactase, fungal lipase and papain; animal nutrition, which include DigeGrain X, DigeGrain XL and DigeGrain M; food processing, including dairy and cheese processing and yeast processing, and non-food processing, including textiles processing, leather and bio-fuels. Its oils and fats processing include oil extraction, oil refining fish oil processing, biodiesel and oleochemicals.
Advanced Enzyme Technologies Ltd. engages in the research, development, manufacture, and sale of enzyme products. The company is headquartered in Thane, Maharashtra and currently employs 322 full-time employees. The company went IPO on 2016-08-01. The firm is focused on the research and development, manufacturing and marketing of approximately 400 products, which is developed from over 68 indigenous enzymes and probiotics. The company provides solutions to various industries, such as human health care and nutrition, animal nutrition, baking, fruit and vegetable processing, brewing and malting, grain processing, protein modification, dairy processing, specialty applications, textile processing and others. The company offers products and solutions for human nutrition, which include serratiopeptidase, fungal lactase, fungal lipase and papain; animal nutrition, which include DigeGrain X, DigeGrain XL and DigeGrain M; food processing, including dairy and cheese processing and yeast processing, and non-food processing, including textiles processing, leather and bio-fuels. Its oils and fats processing include oil extraction, oil refining fish oil processing, biodiesel and oleochemicals.
Revenue Growth: Quarterly revenue grew 2% year-on-year to INR 1,719 million, but fell 7% sequentially. Year-to-date revenue rose 15%.
Profitability Trends: Profit after tax increased 11% year-on-year to INR 432 million, but declined 3% quarter-on-quarter. EBITDA margin dropped to 29% for the quarter, down from 33% last year.
Segment Performance: Human Healthcare revenue declined 6% YoY due to lower pharma and nutrition sales, while Animal Healthcare and Bio-Processing segments saw strong growth.
Tariff Relief: Management noted recent US tariff reductions, expecting a modest positive impact but emphasized continued market uncertainty and margin sensitivity.
R&D Expansion: New R&D center in Nashik to focus on strain development, protein engineering, and fermentation, aiming for long-term product pipeline growth.
US Market Cautious Optimism: Management sees more inquiries and interest from the US market and expects improved performance if macro conditions remain stable.
No Immediate CapEx: No major capacity expansions planned this year except for R&D; larger expansion possible in FY '28–'29.
B2C Strategy: B2C business separated under NutraZyme, currently small but with plans for long-term growth and potential partnerships.
